Choosing Between Access USA and SCOPE: An RWE Strategy Guide

I have spent 11 years in pharma commercial operations and managed markets. I’ve seen the same pattern repeat every spring: someone in RWE or patient access operations asks, "Should I go to Access USA or SCOPE?" They usually frame it around "networking."

Networking is not a strategy. It is a vague metric that makes it impossible to justify your travel budget. When I build my post-conference spreadsheets, I don’t track "who I shook hands with." I track "who influenced the formulary" and "whose data actually moved the needle on pricing."

If you are trying to decide where to spend your conference dollars for your real-world evidence programming, stop looking for "great networking." Start looking for who is actually solving your specific friction points in patient access operations and trial planning resource use.

The Fundamental Split: Access USA vs. SCOPE

The choice between Access USA and SCOPE isn’t about which event is "better." It’s about whether you are fighting the war on the payer front or the clinical execution front.

Access USA is built for the managed care ecosystem. It is where you go to understand the shifting landscape of PBM rebates, HTA pressure, and the nuances of plan-level formulary execution. If your struggle is "Why won't the payer cover this?" you go to Access USA.

SCOPE (the Summit for Clinical Ops Executives) is built for trial planning resource use. It is technical, clinical, and data-heavy. If your struggle is "How do I make my trial data relevant enough to be useful for HEOR?" you go to SCOPE.

When to choose Access USA

Choose Access USA if your primary hurdle is the payer barrier. This is the place to benchmark your managed care strategy against industry peers. You are there to understand the shifting expectations of the C-suite in large national plans and regional insurers.

The conversation here is heavily weighted toward:

• Pricing and Affordability: Understanding the pressure from HTA (Health Technology Assessment) bodies and internal formulary committees.
• Health System Adoption: How IDNs (Integrated Delivery Networks) are negotiating their own risk-based contracts.
• Regulatory Shifts: The downstream effects of drug price transparency requirements.

If you need to know how the latest CMS guidance will impact your patient support programs, this is the room to be in.

When to choose SCOPE

Choose SCOPE if you are knee-deep in real-world evidence programming and site selection. This is the forum for clinical trial design. If you are struggling with patient recruitment, retention, or the digitization of site data collection, this is where you find the vendors and tech partners who are actually doing the work.

The conversation here is weighted toward:

• Digital Tools in Evidence Generation: Using sensors, wearables, and remote patient monitoring to create cleaner datasets.
• Clinical Trial Planning: Optimizing the sites that can handle complex protocols without breaking the budget.
• Operational Efficiency: Reducing the time it takes to get from "concept" to "first patient in."

The Intersections: AMCP, THMA, and ACCC

You cannot talk about access or RWE in a vacuum. Your choice between Access USA and SCOPE should be informed by your involvement in the broader professional organizations like AMCP, The Health clinical operations and market access Management Academy (THMA), and the Association of Cancer Care Centers (ACCC).

If you are an AMCP attendee, Access USA will feel like a natural extension of your workflow. It translates the high-level policy discussions found at AMCP meetings into a commercial strategy. However, if your RWE is specifically tied to oncology, the ACCC provides the ground truth on how those drugs are actually handled in community oncology settings—a perspective often missed at purely commercial conferences.

THMA is the outlier. If your focus is high-level health system executive roundtables, the Academy gives you the "what" (the C-suite perspective), while Access USA gives you the "how" (the contract terms and access hurdles).

Comparison Matrix for Decision Making

I track events using a simple comparison table. If the objectives of the event don't map to these buckets, I don't go. Here is how I weigh the two:

Metric Access USA SCOPE Primary Focus Managed Markets & Payer Strategy Clinical Ops & Data Generation Key Stakeholders Payers, PBMs, Market Access Heads Clinical Ops leads, Data Scientists Biggest Value Formulary pull-through tactics Trial execution and digital tools Ideal Attendee Managed Markets, RWE Policy RWE Program Leads, Clinical Ops

A Note on "Digital Tools" and Site-Level UI

One thing that consistently irritates me at these conferences is the "tech theater." Every booth will claim to have a "revolutionary platform" for RWE. Take a step back and look at the actual user interface—the tools they show you on the showroom floor.

Ironically, you can judge a company's commitment to user-centered design by how they handle the basics. Look at the Cookie Law Info plugin UI on their demo sites. If a site is cluttered with aggressive pop-ups, poorly coded consent bars, and slow-loading modals, they are likely not focusing on the user experience of your clinical trial site staff.

If a vendor can’t manage a clean, efficient browser-based experience, how do you expect them to handle complex real-world evidence programming or trial planning resource use in the field? Pay attention to the UI; it’s a proxy for how they treat the end-user (the HCP or the patient).

The "Monday Morning" Reality Check

After any conference, I ask myself one question: "What would I do differently on Monday?"

If you attend Access USA, your Monday should involve a review of your current formulary status vs. your competitors. You should be drafting notes on how to refine your value prop based on the latest payer "ask" you heard in the corridors. If you leave without a concrete change to your managed care strategy, you wasted your time.

If you attend SCOPE, your Monday should involve a audit of your trial planning resource use. Are your sites struggling with specific data collection points? Did you find a digital tool that can automate that? If you don't have a plan to implement a new tool or change a process, you were just on vacation.

Final Verdict: Which one to pick?

Stop overpromising the ROI of "networking." Pick the event that solves your current bottleneck.

• Go to Access USA if: Your brand is established, your trial data is mostly set, and your primary goal is to lower barriers to entry at the pharmacy level or with hospital formularies.
• Go to SCOPE if: You are still in the mid-to-late stage of building your RWE portfolio, or if you have a massive clinical execution bottleneck that is threatening your timeline.

Don't be the person walking the floor without a plan. Have your spreadsheet, have your list of targets, and for heaven's sake, stop using the word "synergy." It doesn't get you a better spot on the formulary.